Aquestive Therapeutics (AQST) Research Coverage Started at Wedbush
Wedbush initiated coverage on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research report sent to investors on Wednesday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $33.00 price objective on the stock.
Several other brokerages also recently weighed in on AQST. JMP Securities started coverage on shares of Aquestive Therapeutics in a report on Monday, August 20th. They issued an outperform rating and a $29.00 target price on the stock. Royal Bank of Canada started coverage on shares of Aquestive Therapeutics in a report on Monday, August 20th. They issued an outperform rating and a $23.00 target price on the stock. Finally, BMO Capital Markets started coverage on shares of Aquestive Therapeutics in a report on Monday, August 20th. They issued an outperform rating on the stock.
Shares of NASDAQ:AQST opened at $16.52 on Wednesday. Aquestive Therapeutics has a fifty-two week low of $14.75 and a fifty-two week high of $20.70.
In other news, Director Douglas K. Bratton bought 165,000 shares of the stock in a transaction dated Tuesday, July 24th. The shares were acquired at an average price of $15.00 per share, with a total value of $2,475,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
Featured Article: What is the Dow Jones Industrial Average (DJIA)?
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.